TRVN Trevena Inc

Trevena Inc is a clinical stage biopharmaceutical company. It discovers, develops and commercialize therapeutics that use a novel approach to target G protein coupled receptors.

As of 10/15/2021     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  01/31/2014
Outstanding shares:  164,508,838
Average volume:  964,763
Market cap:   $190,830,252
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    89532E109
ISIN:        US89532E1091
Valuation   (See tab for details)
PE ratio:   -4.54
PB ratio:   2.07
PS ratio:   55.22
Return on equity:   -45.62%
Net income %:   -1,194.62%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy